Multiple clinical trialsincluding SUSTAIN-6 (semaglutide) and REWIND (dulaglutide)showed significant reductions in major adverse cardiovascular events (MACE) such as: Heart attack Stroke Cardiovascular death This benefit appears to be independent of weight loss , suggesting direct protective effects on the arteries, blood pressure, and cholesterol metabolism
Mitochondrial dysfunction and ROS production can damage the ER, triggering further stress responses ( 3.3 Lysosomal: iron release and autophagic regulation Lysosomes are key organelles for degradation, recycling, and metabolic regulation (77)
Compare that to the 60/40 split some semaglutide studies show, and the difference over a 50-pound weight loss would be an additional 2-7 pounds of preserved lean mass
Additionally, another study demonstrated that the FXR agonist yangonin improved hepatic lipid homeostasis, alleviated cholestasis, and reduced markers of cellular senescence and inflammation in ALD [111]
Reconstruct: 2-8C (refrigerator)